{"url_path":"/sec/sgmo/10-k/2026/item-15","section_key":"item-15","section_title":"Item 15 EXHIBITS AND FINANCIAL STATEMENT SCHEDULES","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-03-30","source_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001628280-26-022029-index.html","accession_number":"0001628280-26-022029","cik":"0001001233","ticker":"SGMO","issuer_name":"SANGAMO THERAPEUTICS, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001628280-26-022029-index.html","primary_entity_key":"0001001233","primary_entity_name":"SANGAMO THERAPEUTICS, INC"},"word_count":2544,"has_tables":true,"body_markdown":"ITEM 15 – EXHIBITS AND FINANCIAL STATEMENT SCHEDULES\n\n(a) The following documents are included as part of this Annual Report on Form 10-K:\n\n1. Financial Statements—See Index to Consolidated Financial Statements in Item 8.\n\n2. Financial Statement Schedules—Not Applicable.\n\n3. Exhibits\n\nExhibit\n\nNumber\nDescription of Document\n\n3.1\n[Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed June 2, 2023).](https://www.sec.gov/Archives/edgar/data/1001233/000162828023020692/sgmo-20230602xex33.htm)\n\n3.2\n[Certificate of Amendment of the Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 5, 2024).](https://www.sec.gov/Archives/edgar/data/1001233/000162828024026903/sgmo-20240605xex31.htm)\n\n3.3\n[Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed December 19, 2022).](https://www.sec.gov/Archives/edgar/data/1001233/000162828022032209/sgmo-20221219xxex31fifth.htm)\n\n4.1\n[Description of Capital Stock](sgmo-20251231xex41.htm)\n\n4.2\n[Form of Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed January 6, 2017).](https://www.sec.gov/Archives/edgar/data/1001233/000119312517003781/d304900dex41.htm)\n\n10.1(+)\n[Amended and Restated 2013 Stock Incentive Plan (the “2013 Plan”) (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed May 10, 2018).](https://www.sec.gov/Archives/edgar/data/1001233/000156459018012641/sgmo-ex102_123.htm)\n\n10.2(+)\n[Amended and Restated 2018 Equity Incentive Plan (the “2018 Plan”) (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed June 2, 2023).](https://www.sec.gov/Archives/edgar/data/1001233/000162828023020692/sgmo2018eiparmarch2023.htm)\n\n10.3(+)\n[Amended and Restated 2018 Equity Incentive Plan of Sangamo Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed June 16, 2025).](https://www.sec.gov/Archives/edgar/data/1001233/000162828025031559/ex-101amendedandrestated20.htm)\n\n10.4(+)\n[2018 Equity Incentive Plan French Stock-Options Sub-Plan (the “French Options Sub-Plan”) (incorporated by reference to Exhibit 10.3 to the Company’s Annual Report on Form 10-K filed March 1, 2019).](https://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex103_614.htm)\n\n10.5(+)\n[2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.1 to the Company’s Registration Statement on Form S-8 filed October 15, 2020).](https://www.sec.gov/Archives/edgar/data/1001233/000119312520269552/d98696dex991.htm)\n\n10.6(+)\n[Form of Restricted Stock Unit Award Agreement under the 2013 Plan (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed June 14, 2013).](https://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex102.htm)\n\n10.7(+)\n[Form of Notice of Grant of Stock Option under the 2013 Plan (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed June 14, 2013).](https://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex103.htm)\n\n10.8(+)\n[Form of Stock Option Agreement under the 2013 Plan (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed June 14, 2013).](https://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex104.htm)\n\n10.9(+)\n[Form of Notice of Grant of Stock Option – Director Initial Grant under the 2013 Plan (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed June 14, 2013).](https://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex105.htm)\n\n10.10(+)\n[Form of Notice of Grant of Stock Option – Director Annual Grant under the 2013 Plan (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed June 14, 2013).](https://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex106.htm)\n\n10.11(+)\n[Form of Automatic Stock Option Agreement under the 2013 Plan (incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K filed June 14, 2013).](https://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex107.htm)\n\n10.12(+)\n[Form of Stock Option Grant Notice and Form of Option Agreement (U.S. employees) under the 2018 Plan (incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K filed June 15, 2018).](https://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex992_12.htm)\n\n10.13(+)\n[Form of Stock Option Grant Notice and Form of Option Agreement (non-employee directors) under the 2018 Plan (incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K filed June 15, 2018).](https://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex993_11.htm)\n\n10.14(+)\n[Form of Stock Option Grant Notice and Form of Option Agreement (U.K. employees) under the 2018 Plan (incorporated by reference to Exhibit 99.4 to the Company’s Current Report on Form 8-K filed June 15, 2018).](https://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex994_10.htm)\n\n10.15(+)\n[Form of Stock Option Grant Notice (French employees) under the 2018 Plan and the French Options Sub-Plan (incorporated by reference to Exhibit 10.14 to the Company’s Annual Report on Form 10-K filed March 1, 2019).](https://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1014_438.htm)\n\n10.16(+)\n[Form of Stock Option Agreement (French Employees) under the 2018 Plan and the French Options Sub-Plan (incorporated by reference to Exhibit 10.15 to the Company’s Annual Report on Form 10-K filed March 1, 2019).](https://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1015_613.htm)\n\n147\n\n[Table of Contents](#i29aeb4416f69482f8f7bc32e0d48731a_7)\n\nExhibit\n\nNumber\nDescription of Document\n\n10.17(+)\n[Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (U.S. employees) under the 2018 Plan (incorporated by reference to Exhibit 99.5 to the Company’s Current Report on Form 8-K filed June 15, 2018).](https://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex995_9.htm)\n\n10.18(+)\n[Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (non-employee directors) under the 2018 Plan (incorporated by reference to Exhibit 99.6 to the Company’s Current Report on Form 8-K filed June 15, 2018).](https://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex996_7.htm)\n\n10.19(+)\n[Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (U.K. employees) under the 2018 Plan (incorporated by reference to Exhibit 99.7 to the Company’s Current Report on Form 8-K filed June 15, 2018).](https://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex997_8.htm)\n\n10.20(+)\n[Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (French employees) under the 2018 Plan and the French RSU Sub-Plan. (incorporated by reference to Exhibit 10.19 to the Company’s Annual Report on Form 10-K filed March 1, 2019).](https://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1019_437.htm)\n\n10.21(+)\n[Amended and Restated Executive Severance Plan of Sangamo Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1001233/000162828023035989/sangamoexecutiveseveranc.htm) [(incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed November 1, 2023).](https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xex103.htm)\n\n10.22(+)\n[Amended and Restated Incentive Compensation Plan (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed May 10, 2018).](https://www.sec.gov/Archives/edgar/data/1001233/000156459018012641/sgmo-ex102_123.htm)\n\n10.23(+)\n[Form of Indemnity Agreement (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed May 11, 2020).](https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xex103.htm)\n\n10.24(+)\n[Employment Agreement between the Company and Alexander (Sandy) Macrae, dated May 17, 2016 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed August 4, 2016).](https://www.sec.gov/Archives/edgar/data/1001233/000156459016022708/sgmo-ex101_285.htm)\n\n10.25(+)\n[Employment Agreement between the Company and Nikunj Jain, dated September 30, 2025](https://www.sec.gov/Archives/edgar/data/1001233/000100123325000024/sgmo-20250930xex102.htm)[(incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed November 6, 2025).](https://www.sec.gov/Archives/edgar/data/1001233/000100123325000024/sgmo-20250930xex102.htm)\n\n10.26(+)\n[Letter Agreement between the Company and Scott Willoughby dated as of August 2, 2021 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed November 4, 2021).](https://www.sec.gov/Archives/edgar/data/0001001233/000162828021021629/sgmo-20210930xex101_employ.htm)\n\n10.27(+)\n[Letter Agreement between the Company and Nathalie Dubois-Stringfellow dated as of September 28, 2022 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed November 3, 2022).](https://www.sec.gov/Archives/edgar/data/1001233/000162828022028168/sgmo-20220930xex101_employ.htm)\n\n10.28(+)\n[Letter Agreement Regarding Alexander (Sandy) Macrae Cash Retention Award](https://www.sec.gov/Archives/edgar/data/1001233/000162828024010788/exhibit1035sangamo-2024c.htm)\n\n10.29\n[Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated May 23, 1997 (incorporated by reference to Exhibit 10.5 to the Company’s Registration Statement on Form S-1 filed February 24, 2000).](https://www.sec.gov/Archives/edgar/data/1001233/000095014900000384/0000950149-00-000384.txt)\n\n10.30\n[First Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated March 12, 2004 (incorporated by reference to Exhibit 10.20 to the Company’s Annual Report on Form 10-K filed February 23, 2005).](https://www.sec.gov/Archives/edgar/data/1001233/000095014905000054/f05860exv10w20.htm)\n\n10.31\n[Second Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated March 15, 2007 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed November 4, 2013).](https://www.sec.gov/Archives/edgar/data/1001233/000119312513425338/d595389dex101.htm)\n\n10.32\n[Third Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated August 1, 2013 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed November 4, 2013).](https://www.sec.gov/Archives/edgar/data/1001233/000119312513425338/d595389dex102.htm)\n\n10.33\n[Fourth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated June 10, 2016 (incorporated by reference to Exhibit 10.33 to the Company’s Annual Report on Form 10-K filed March 1, 2019).](https://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1033_728.htm)\n\n10.34\n[Fifth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated July 10, 2017 (incorporated by reference to Exhibit 10.34 to the Company’s Annual Report on Form 10-K filed March 1, 2019).](https://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1034_727.htm)\n\n10.35\n[Sixth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated May 11, 2018 (incorporated by reference to Exhibit 10.9 to the Company’s Quarterly Report on Form 10-Q filed August 8, 2018).](https://www.sec.gov/Archives/edgar/data/1001233/000156459018020536/sgmo-ex109_61.htm)\n\n10.36\n[Seventh Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated May 20, 2020 (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q filed August 5, 2020).](https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex104.htm)\n\n10.37\n[Eighth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated May 29, 2020 (incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q filed August 5, 2020).](https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex105.htm)\n\n148\n\n[Table of Contents](#i29aeb4416f69482f8f7bc32e0d48731a_7)\n\nExhibit\n\nNumber\nDescription of Document\n\n10.38\n[Ninth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated January 4, 2021 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed May 4, 2021).](https://www.sec.gov/Archives/edgar/data/0001001233/000162828021008878/sgmo-20210331xex102.htm)\n\n10.39\n[Amended and Restated Office and Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated October 18, 2021 (incorporated by reference to Exhibit 10.34 to the Company’s Annual Report on Form 10-K filed February 24, 2022).](https://www.sec.gov/Archives/edgar/data/1001233/000162828022003819/sgmo-20211231xex1045_ame.htm)\n\n10.40\n[Lease Agreement between the Company and Marina Boulevard Property, LLC dated November 3, 2017 (incorporated by reference to Exhibit 10.21 to the Company’s Annual Report on Form 10-K filed March 1, 2018).](https://www.sec.gov/Archives/edgar/data/1001233/000156459018004163/sgmo-ex1021_830.htm)\n\n10.41\n[First Amendment to Lease Agreement between the Company and Marina Boulevard Property, LLC dated January 1, 2019 (incorporated by reference to Exhibit 10.37 to the Company’s Annual Report on Form 10-K filed March 1, 2019).](https://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1037_729.htm)\n\n10.42\n[Second Amendment to Lease Agreement between the Company and PPF OFF 7000 Marina Boulevard LP dated February 5, 2024 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed May 9, 2024)](https://www.sec.gov/Archives/edgar/data/1001233/000162828024022194/secondamendmenttoleaseag.htm)\n\n10.43\n[Third Amendment to Lease Agreement between the Company and PPF OFF 7000 Marina Boulevard LP dated July 3, 2024 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed November 12, 2024).](https://www.sec.gov/Archives/edgar/data/1001233/000162828024047102/thirdamendmenttoleaseagr.htm)\n\n10.44\n[Fourth Amendment to Lease Agreement between the Company and PPF OFF 7000 Marina Boulevard LP dated August 25, 2025 (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed November 6, 2025).](https://www.sec.gov/Archives/edgar/data/1001233/000100123325000024/sgmo-20250930xex103.htm)\n\n10.45\n[Open Market Sale Agreement between the Company and Jefferies LLC, dated August 5, 2020 (incorporated by reference to Exhibit 1.1 to the Company’s Quarterly Report on Form 10-Q filed August 5, 2020).](https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm)\n\n10.46\n[Amendment No. 1 to Open Market Sale Agreement between the Company and Jefferies LLC, dated May 5, 2021 (incorporated by reference to Exhibit 1.3 to the Company’s Registration Statement on Form S-3 filed May 5, 2021).](https://www.sec.gov/Archives/edgar/data/0001001233/000119312521151792/d124856dex13.htm)\n\n10.47\n[Amendment No. 2 to Open Market Sale Agreement between the Company and Jefferies LLC, dated December 23, 2022 (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed December 23, 2022).](https://www.sec.gov/Archives/edgar/data/1001233/000162828022032552/exhibit11amendmentno2toope.htm)\n\n10.48\n[Amendment No. 3 to Open Market Sale Agreement between the Company and Jefferies LLC, dated March 7, 2023 (incorporated by reference to Exhibit 1.1 to the Company’s Quarterly Report on Form 10-Q filed May 8, 2023).](https://www.sec.gov/Archives/edgar/data/1001233/000162828023006626/exhibit11-amendmentno3toop.htm)\n\n10.49\n[Amendment No. 4 to the Open Market Sale Agreement between the Company and Jefferies LLC, dated November 12, 2024 (incorporated by reference to Exhibit 1.2 to the Company’s Registration Statement on Form S-3 filed November 12, 2024).](https://www.sec.gov/Archives/edgar/data/1001233/000114036124046238/ny20037443x1_ex1-2.htm)\n\n10.50†\n[Amended and Restated Collaboration and License Agreement between the Company and Shire International GmbH, dated September 1, 2015 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed October 30, 2015).](https://www.sec.gov/Archives/edgar/data/1001233/000156459015009009/sgmo-ex101_99.htm)\n\n10.51⁑\n[Collaboration and License Agreement between the Company and Pfizer Inc., dated May 10, 2017 (](https://www.sec.gov/Archives/edgar/data/1001233/000162828023004666/exhibit1053-pfizersb525l.htm)[incorporated by reference to Exhibit 10.53 to the Company’s Annual Report on Form 10-K filed February 23, 2023)](https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1045.htm)[.](https://www.sec.gov/Archives/edgar/data/1001233/000162828023004666/exhibit1053-pfizersb525l.htm)\n\n10.52†\n[Research Collaboration and License Agreement between the Company and Pfizer Inc., dated December 28, 2017 (incorporated by reference to Exhibit 10.40 to the Company’s Annual Report on Form 10-K filed March 1, 2018).](https://www.sec.gov/Archives/edgar/data/1001233/000156459018004163/sgmo-ex1040_689.htm)\n\n10.53⁑\n[License Agreement between the Company and Genentech, Inc., dated August 2, 2024 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed November 12, 2024).](https://www.sec.gov/Archives/edgar/data/1001233/000162828024047102/sgmo-20240930xex101.htm)\n\n10.54\n[Form of](https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/d816036dex41.htm)[202](https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/d816036dex41.htm)[4](https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/d816036dex41.htm)[Pre-Funded Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed March 25, 2024).](https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/d816036dex41.htm)\n\n10.55\n[Form of](https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/d816036dex42.htm)[202](https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/d816036dex42.htm)[4](https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/d816036dex42.htm)[Purchase Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed March 25, 2024).](https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/d816036dex42.htm)\n\n10.56\n[Form of](https://www.sec.gov/Archives/edgar/data/1001233/000114036125018697/ny20048472x3_ex4-1.htm)[2025](https://www.sec.gov/Archives/edgar/data/1001233/000114036125018697/ny20048472x3_ex4-1.htm)[Pre-Funded Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed May 1](https://www.sec.gov/Archives/edgar/data/1001233/000114036125018697/ny20048472x3_ex4-1.htm)[3](https://www.sec.gov/Archives/edgar/data/1001233/000114036125018697/ny20048472x3_ex4-1.htm)[, 2025).](https://www.sec.gov/Archives/edgar/data/1001233/000114036125018697/ny20048472x3_ex4-1.htm)\n\n10.57\n[Form of](https://www.sec.gov/Archives/edgar/data/1001233/000114036125018697/ny20048472x3_ex4-2.htm)[2025](https://www.sec.gov/Archives/edgar/data/1001233/000114036125018697/ny20048472x3_ex4-2.htm)[Purchase Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed May 1](https://www.sec.gov/Archives/edgar/data/1001233/000114036125018697/ny20048472x3_ex4-2.htm)[3](https://www.sec.gov/Archives/edgar/data/1001233/000114036125018697/ny20048472x3_ex4-2.htm)[, 2025).](https://www.sec.gov/Archives/edgar/data/1001233/000114036125018697/ny20048472x3_ex4-2.htm)\n\n10.58\n[Form of](https://www.sec.gov/Archives/edgar/data/1001233/000119312526036792/d101629dex41.htm)[2026](https://www.sec.gov/Archives/edgar/data/1001233/000119312526036792/d101629dex41.htm)[Pre-Funded Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed February 4, 2026).](https://www.sec.gov/Archives/edgar/data/1001233/000119312526036792/d101629dex41.htm)\n\n149\n\n[Table of Contents](#i29aeb4416f69482f8f7bc32e0d48731a_7)\n\nExhibit\n\nNumber\nDescription of Document\n\n10.59\n[Form of](https://www.sec.gov/Archives/edgar/data/1001233/000119312526036792/d101629dex42.htm)[2026](https://www.sec.gov/Archives/edgar/data/1001233/000119312526036792/d101629dex42.htm)[Purchase Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed February 4, 2026).](https://www.sec.gov/Archives/edgar/data/1001233/000119312526036792/d101629dex42.htm)\n\n19.1\n[Insider Trading Policy (incorporated by reference to Exhibit 1](https://www.sec.gov/Archives/edgar/data/1001233/000162828025013088/sgmo-20241231xexx191.htm)[9.1](https://www.sec.gov/Archives/edgar/data/1001233/000162828025013088/sgmo-20241231xexx191.htm)[to the Company’s Annual Report on Form 10-K filed March 17, 2025).](https://www.sec.gov/Archives/edgar/data/1001233/000162828025013088/sgmo-20241231xexx191.htm)\n\n21.1\n[Subsidiaries of the Company.](sgmo-20251231xexx211.htm)\n\n23.1\n[Consent of Independent Registered Public Accounting Firm.](sgmo-20251231xexx231.htm)\n\n24.1\n[Power of Attorney (included on signature page).](#i29aeb4416f69482f8f7bc32e0d48731a_184)\n\n31.1\n[Rule 13a-14(a) Certification of Principal Executive Officer.](sgmo-20251231xex311.htm)\n\n31.2\n[Rule 13a-14(a) Certification of Principal Financial Officer.](sgmo-20251231xex312.htm)\n\n32.1*\n[Certification Pursuant to 18 U.S.C. Section 1350.](sgmo-20251231xex321.htm)\n\n97\n[Incentive Compensation Recoupment Policy](https://www.sec.gov/Archives/edgar/data/1001233/000162828024010788/exhibit1024incentivecomp.htm)[(incorporated by reference to Exhibit 10.40 to the Company’s Annual Report on Form 10-K filed March 17, 2025)](https://www.sec.gov/Archives/edgar/data/1001233/000162828024010788/exhibit1024incentivecomp.htm)[.](https://www.sec.gov/Archives/edgar/data/1001233/000162828024010788/exhibit1024incentivecomp.htm)\n\n101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n101.SCHXBRL Taxonomy Extension Schema Document\n\n101.CALXBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEFXBRL Taxonomy Extension Definition Linkbase Document\n\n101.LABXBRL Taxonomy Extension Label Linkbase Document\n\n101.PREXBRL Taxonomy Extension Presentation Linkbase Document\n\n104\nThe cover page from Sangamo’s Annual Report on Form 10-K for the year ended December 31, 2025, is formatted in Inline XBRL and it is contained in Exhibit 101\n\n_______________________\n\n†    Confidential treatment has been granted for certain information contained in this document pursuant to an order of the SEC. Such information has been omitted and filed separately with the SEC.\n\n⁑    Certain portions of this exhibit (indicated by “[*]”) have been omitted in accordance with 17 CFR § 229.601(b).\n\n(+)    Indicates management contract or compensatory plan or arrangement.\n\n*    The certifications attached as Exhibit 32.1 accompany this Annual Report on Form 10-K pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.\n\nThe agreements and other documents filed as exhibits to this Annual Report on Form 10-K are not intended to provide factual information or other disclosure other than with respect to the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representations and warranties made by us in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time."}